Trillium Therapeutics Inc (TRIL) Return on Equity ROE from the third quarter 2021 to third quarter 2020 and annually, average high and low, overall ranking from Sep 30 2021 to Sep 30 2020 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Trillium Therapeutics Inc   (NASDAQ: TRIL)

Trillium Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Trillium Therapeutics Inc in the third quarter 2021?
Trillium Therapeutics Inc recorded a cumulative net loss of $-34 million during 12 months ending in the third quarter 2021, resulting in a negative return on equity (ROE) of -16.33%.

Within the Major Pharmaceutical Preparations industry 191 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2021 from 0 to 3594.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2021)
III. Quarter		 (Jun 30 2021)
II. Quarter		 (Mar 31 2021)
I. Quarter		 (Dec 31 2020)
IV. Quarter		 (Sep 30 2020)
III. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - -33.35 % - -
Net Income (TTM) in Millions -34 -27 -32 -27 22
Return On Equity (TTM) -16.33 % -17.01 % -29.64 % -49.31 % -
TRIL's Total Ranking # 3594 # 0 # 0 # 0 #
Equity (TTM) in Millions 192 209 217 219 -1
Seq. Equity Change -8.31 % -3.64 % -0.68 % - -
Seq. Net Income Change - - - - -

Back to TRIL Management Effectiveness >> TRIL's 5 Years Annual ROE >> Compare TRIL ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 192
Sector # 482
Overall # 3594

Return On Equity Statistics
High Average Low
105.66 %
-25.04 %
-145.22 %
(Dec 31 2018)   (Dec 31 2020)





TRIL Annual Return On Equity (Dec 31 2020)
2020		 (Dec 31 2019)
2019		 (Dec 31 2018)
2018		 (Dec 31 2017)
2017
Total Equity in Millions 279 -1 28 62 0
Y / Y Equity Change - - -55.77 % - -
Net Income in Millions 59 38 -33 45 0
Y / Y Net Income Change 55.84 % - - - -
Return On Equity 21.28 % - -119.16 % 72.29 % -

Back to TRIL Management Effectiveness >> TRIL's 5 Years Annual ROE >> Compare TRIL ROE to its Competitors




Annual Roe Comment
In 2020 ROE improved to 21.28 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
TRIL's' Return on Equity at Yahoo Finance
TRIL's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for TRIL's Competitors
Subscribers only: Roe for Trillium Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for TRIL's Customers




Companies with similar Return On Equity at Sep 30 2021, within Healthcare Sector ROE

Date modified: 2026-09-26T07:33:43+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.